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Abstract
Recent studies suggest that variation in complex disorders (e.g., schizophrenia) is explained by a large number of genetic
variants with small effect size (Odds Ratio,1.05–1.1). The statistical power to detect these genetic variants in Genome Wide
Association (GWA) studies with large numbers of cases and controls (,15,000) is still low. As it will be difficult to further
increase sample size, we decided to explore an alternative method for analyzing GWA data in a study of schizophrenia,
dramatically reducing the number of statistical tests. The underlying hypothesis was that at least some of the genetic
variants related to a common outcome are collocated in segments of chromosomes at a wider scale than single genes. Our
approach was therefore to study the association between relatively large segments of DNA and disease status. An
association test was performed for each SNP and the number of nominally significant tests in a segment was counted. We
then performed a permutation-based binomial test to determine whether this region contained significantly more
nominally significant SNPs than expected under the null hypothesis of no association, taking linkage into account. Genome
Wide Association data of three independent schizophrenia case/control cohorts with European ancestry (Dutch, German,
and US) using segments of DNA with variable length (2 to 32 Mbp) was analyzed. Using this approach we identified a region
at chromosome 5q23.3-q31.3 (128–160 Mbp) that was significantly enriched with nominally associated SNPs in three
independent case-control samples. We conclude that considering relatively wide segments of chromosomes may reveal
reliable relationships between the genome and schizophrenia, suggesting novel methodological possibilities as well as
raising theoretical questions.
Citation: Gladwin TE, Derks EM, (GROUP), Rietschel M, Mattheisen M, et al. (2012) Segment-Wise Genome-Wide Association Analysis Identifies a Candidate Region
Associated with Schizophrenia in Three Independent Samples. PLoS ONE 7(6): e38828. doi:10.1371/journal.pone.0038828
Editor: Dan E. Arking, Johns Hopkins University, United States of America
Received November 7, 2011; Accepted May 14, 2012; Published June 18, 2012
Copyright:  2012 Gladwin et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: Genotyping of the Dutch samples was sponsored by NIMH funding, RO1 MHO78075 (to R.A.O.). Funding support for Linking Genome-Wide Association
Study of Schizophrenia was provided by Foundation for the National Institutes of Health and the genotyping of samples was provided through the Genetic
Association Information Network (GAIN). The dataset used for the analyses described in this manuscript was obtained from the GAIN Database found at http://
view.ncbi.nlm.nih.gov/dbgap-controlled through dbGaP accession number phs000021. The GROUP study was supported by the Geestkrachtprogramme of the
Dutch Health Research Council(ZON-MW, grant number 10-000-1002); the EU SeventhFramework Programme (consortium name: EU-GEI)and matching funds
from participating universities andmental health care organizations (Site Amsterdam: Academic Psychiatric Centre AMC, Ingeest, Arkin, Dijk enDuin, Rivierduinen,
ErasmusMC, GGZ Noord HollandNoord; Site Utrecht: University Medical Centre Utrecht,Altrecht, Symfora, Meerkanten, Riagg Amersfoort,Delta; Site Groningen:
University Medical CenterGroningen, Lentis, GGZ Friesland, GGZ Drenthe,Adhesie, Mediant, GGZ De Grote Rivieren and Parnassia psycho-medical centre; Site
Maastricht: MaastrichtUniversity Medical Center, GGZ Eindhoven, GGZMidden-Brabant, GGZ Oost-Brabant, GGZ Noord-Midden Limburg, Mondriaan Zorggroep,
Prins Claus-centrum Sittard, RIAGG Roermond, Universitair Centrum Sint-Jozef Kortenberg, CAPRI University ofAntwerp, PC Ziekeren Sint-Truiden, PZ Sancta
MariaSint-Truiden, GGZ Overpelt, OPZ Rekem). The German genome-wide association study of schizophrenia was supported by the German Federal Ministry of
Education and Research (BMBF), within the context of the National Genome Research Network plus (NGFNplus), and the MooDS-Net (grant 01GS08144 to S.C. and
M.M.N., grant 01GS08147 to M.R.). M.M.N. also received support from the Alfried Krupp von Bohlen und Halbach-Stiftung. German control genotypes were derived
from community-based cohorts collected in the framework of the PopGen (Dr. Stefan Schreiber. Kiel), KORA (Dr. H.-Erich Wichmann, Munich), and Heinz-Nixdorf-
Recall (Dr. Susanne Moebus, Essen) studies. PopGen and KORA controls were made available to participants of NGFNplus for use as universal controls in genetic
studies of the funded disease phenotypes. Dr. E.M. Derks is supported by the Netherlands Scientific Organization (NWO; project number 451-080-010). Statistical
analyses were carried out on the Genetic Cluster Computer (http://www.geneticcluster.org) which is financially supported by the Netherlands Scientific
Organization (NWO 480-05-003). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: e.m.derks@amc.uva.nl
. These authors contributed equally to this work.
" Membership of the Genetic Risk and Outcome of Psychosis (GROUP) is provided in the Acknowledgments.
PLoS ONE | www.plosone.org 1 June 2012 | Volume 7 | Issue 6 | e38828
Introduction
The statistical power to detect genetic effects in Genome Wide
Association (GWA) studies of complex disorders is hindered by
multiple testing problems and small effect sizes of single SNPs [1].
Alternative methods for analyzing GWA data which consider
larger scale relationships between phenotype and SNP or single
genes may help address these problems, and may have biological
implications concerning the organization of genetic information.
The aim of the current study was to determine whether relatively
broad segments of the genome, as opposed to specific SNPs, could
be related to schizophrenia. Our approach was to test per segment
whether significantly higher numbers of nominally related SNPs
were present than expected based on chance.
Schizophrenia is a complex psychiatric disorder which is to a
large extent influenced by genetic effects [2]. Recently, based on
the findings of Genome Wide Association (GWA) studies it has
been suggested that about 30% of the genetic variation is
explained by a large number of SNPs with small effect sizes [1].
The statistical power to detect the effect of single SNPs is low
which may explain the missing heritability for schizophrenia [3].
In an effort to deal with this statistical problem, Moskvina and
colleagues [4] used a gene-based approach to perform a GWA by
determining the excess of nominally significant (P,.05; P,.01,
and P,.001) disease associated SNPs within genes, observing that
significantly more SNPs within genes showed evidence for
association with schizophrenia than expected by chance. Although
these results are important, a limitation of the method is the a
priori exclusion of the genome outside the genic regions. Further,
only segments at the scale of single genes were considered. True
association signals may also be located outside the boundaries of
genes; for example, studies have shown the existence of long-range
regulatory elements which suggest that the effects of functional
gene domains may extend far beyond their transcription unit [5].
In this study, we will study the excess of nominally significant
SNPs within large segments (2–32 Mbp) of the genome. This
approach uses all genome-wide genotype data, searching for
possible clusters in the distribution of disease-related variation over
the genome without prior restrictions to gene locations. The
rationale of this approach is the premise that genes contributing to
schizophrenia may not be randomly distributed across the genome
but may be clustered in coordinated expression domains [6] or
chromosomal territories [7]. Woo and colleagues have examined
microarray data collected in mice and humans and investigated
whether genes showing coexpression (i.e., genes with comparable
expression profiles) are clustered in the genome. They have
detected strong and statistically significant enrichment of coex-
pression among pairs of genes whose distances fall within the sub-
megabase range. In addition, they report a weaker but still
significant enrichment of coexpression among genes with distances
spanning tens of megabases. Lieberman-Aiden and colleagues
used Hi-C to study long-range interactions between specific pairs
of loci [8]. In Hi-C, cells are fixed with formaldehyde, causing
interacting loci to be bound to one another by means of covalent
DNA-protein cross-links [9]. Lieberman-Aiden showed that the
probability of physical contact decreases as a function of genomic
distance on chromosome 1. We therefore developed the idea that
chromosomal segments potentially represent meaningful entities in
the sense that SNPs within a particular segment have a higher
chance to be involved in the same biological or functional pathway
compared to SNPs from different segments. We varied the
segment sizes from 2 Mbp to 32 Mbp as we wanted to explore a
wide variety of segment sizes and these sizes appear to be
reasonable based on the results of the studies on genetic
coexpression.
The aim of this paper is to present a novel, data-driven
approach for the analysis of GWA data based on the possibility
that subsets of weakly associated SNPs are located within relatively
broad segments of DNA, spanning both genic and intergenic
locations. Tests performed on three independent data sets showed
that a relatively broad region of chromosome 5 is significantly
associated with schizophrenia. The result provides novel informa-
tion on the genetic basis of schizophrenia and supports the
assumption that at least part of the genetic variation underlying
schizophrenia involves genetic information contained within
contiguous segments of the genome.
Results
One region on chromosome 5q was found to be associated with
schizophrenia in all three samples, for all segments widths above
2 Mbp: chromosome 5q23.3-q31.3 (128–136 Mbp). Different
widths showed only small variations in the borders of the region:
width 4 Mbp, 132–136 Mbp; width 8 Mbp, 128–136 Mbp; width
16 Mbp, 120–136 Mbp; width 32 Mbp, 128–160 Mbp. When
testing the significance of the regions using Fisher’s combined
probability test for combining p-values, the segments for the 16
and 32 Mbp width survived stringent Bonferroni correction. In the
5q23.3-q31.3 (128–136 Mbp) region, the number of observed
nominally significantly SNPs was higher than the expected
number in the sample from the Netherlands (N observed= 216;
N expected = 66), the GAIN sample (N observed= 189; N
expected = 95), and the German sample (N observed= 119; N
expected = 66). As described in the methods section, the signifi-
cance in each cohort was determined based on permutation
testing, to account for possible linkage disequilibrium in this
region. The results of these tests are summarized in Table 1.
Manhattan plots of the 22 autosomal chromosomes and the
significantly associated region at chromosome 5 are shown in
Figures 1 and 2, respectively.
The region was found to contain various (disease-related)
genes, as shown in Table 2. Table 2 includes information on the
genes in that region that have previously reported to be
associated with disease as denoted in the UCSC Genome
Bioinformatics site (NCBI36/hg18) (http://genome.ucsc.edu/).
Furthermore, we included information on the genes that were
previously found to be associated with schizophrenia; this
information was obtained from the Schizophrenia Research
Forum (www.schizophreniaresearchforum.org). Finally, of all
disease-related genes reported in the UCSC Genome Bioinfor-
matics site, we denoted the phenotypes with which these genes
have been associated.
Follow-up analyses were performed for the chromosome 5 (128–
136 Mbp) segment width to test the sensitivity of the results to the
parameters of the analysis (Table 3). In the original analyses, the
threshold for nominal significance was .05. The analysis was
repeated with different values for the nominal criterion level per
SNP. For p= 0.01, a trend was found for the same region on
chromosome 5,. For p= 0.1, the region remained significantly
associated with schizophrenia status. Second, the original analysis
(nominal p= .05) was repeated following EIGENSTRAT [10]
correction, after which the region remained significant in two
samples (p = 0.004, p = 0.001), and was close to the cut-off of .0264
in the remaining sample (p = 0.04). Again, the Fisher’s combined
probability tests show highly similar results with p-values below the
cut-off of 1.8 E-5 for nominal significance levels of .05 and .1 but
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Table 1. Metasignificance of segments located in chromosome 5 (128–160 Mbp).
Segment width [Mbp] Replicable region [Mbp] p (Netherlands) p (GAIN) p (Germany)
Fisher’s combined
probability test
4 chr5: 132–136 0.017 0.009 0.025 3.49 E-4
8 chr5: 128–136 0.001 0.008 0.026 2.80 E-5
16 chr5: 120–136 0.001 0.016 0.013 2.80 E-5
16 chr5: 128–144 0.001 0.021 0.001 3.67 E-6
32 chr5: 128–160 0.001 0.023 0.001 3.98 E-6
Note. Segment width refers to the width of regions over which tests of the number of nominally significant SNPs were tested. The replicable region indicates the
location of the segment. The p-values provide the results of permutation based tests.
doi:10.1371/journal.pone.0038828.t001
Figure 1. ‘‘Manhattan plot of the 22 autosomal chromosomes’’. This figure shows at the y–axis the p-values of the SNPs in a GWA analysis.
The chromosomes are shown at the x-axis. The red line indicates a p-value of 10-7, the blue line indicates a p-value of 10-5 and the green line
indicates a p-value of .05.
doi:10.1371/journal.pone.0038828.g001
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not for p = .01. For an explanation of the rationale for the chosen
cut-off values of .0264 and 1.8 E-5, please see the methods section.
Discussion
The segment-wise method decreases the number of statistical
tests from around 500,000 SNPs to the order of hundreds or
thousands of segments. The fact that broad regions of 4 to 32 Mbp
widths (but not of 2 Mbp) were found to contain increased
numbers of nominally significant associated single SNPs suggests
that the combination of information over larger segments can
increase the strength of the segment-wise association signal.
Clearly, the current approach is only appropriate for hypotheses
or methods aimed at regionally clustered genetic information.
Further, the increased power to detect association using large
segments of the genome comes at the cost of a reduction in
regional specificity. Based on our results, we do not know which
specific genetic polymorphisms are involved with schizophrenia.
The current method could therefore be seen as a first-sweep
method which identifies regions of interest which should then be
studied more extensively, but it may also indicate a distribution of
schizophrenia-related genetic information that involves clusters
over the genome.
There are at least three possible explanations for a finding of
apparently clustered genetic information, measured via the
combined effect of a large number of neighbouring SNPs. First,
it is possible that the positive association arises due to multiple
schizophrenia associated genes which are located in the same
segment. A number of previously reported candidate genes for
schizophrenia are indeed located in the chromosome 5 region
Figure 2. ‘‘Manhattan plot of the top segment located at chromosome 5 (128–136 Mbp)’’. This figure shows at the y–axis the p-values of
the SNPs located at chromosome 5 (128–136 Mbp). The chromosomes are shown at the x-axis. The red line indicates a p-value of 10-7, the blue line
indicates a p-value of 10-5 and the green line indicates a p-value of .05.
doi:10.1371/journal.pone.0038828.g002
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which was highlighted in this study. Second, a more speculative
but intriguing possibility is that associations between disease and
the genome may exist on a different level of resolution; i.e.,
information may be present in the higher-order structure of the
genome [11]; as well as in single genes. The higher-order
organization of the genome comprises the folding of the DNA
into chromatin fibers, chromosome domains, and ultimately,
chromosomes and has been shown to be functionally important for
gene regulation and control of gene expression programs [12].
The spatial organization of the genome may facilitate the
communication between genomic elements by bringing the
regulatory elements in close spatial proximity [11]. We could
therefore hypothesize that it is advantageous for genes which are
related to the same biological pathway to be physically close (i.e.,
in the same chromosome domain) since that could potentially
facilitate the regulation of the co-expression of these genes. A third
possibility is that the chromosome 5q region includes a series of
independent, segregating indels that are in LD with the SNPs in
this region. This would imply that the rare genetic variants result
in synthetic associations between case-control status and the
common SNPs [13].
The fact that we have found regional clustering of association
signal at chromosome 5q (128–136 Mbp) suggests that a relatively
large proportion of the genes in this segment plays a role in
schizophrenia. Whether the genes in this segment are involved in
the same biological or functional pathway should be investigated
in future studies. A further question for future research is whether
our approach could be relevant for other psychiatric or non-
psychiatric complex traits. If the clustering of association signal is
indeed explained by the higher-order organization of the genome,
we might expect similar findings for other complex traits in which
many genes within multiple biological pathways are involved.
Colocalization of genes might be advantageous for other complex
phenotypes for which the coexpression of many different genes has
to be regulated. It would therefore be interesting to apply this
approach to other complex phenotypes, such as height. In
addition, we could investigate the role of the 5q region in, for
example, bipolar disorder which is partly influenced by the same
genetic risk factors as schizophrenia [1].
Genetic variants in the 5q region have previously been found to
be associated with schizophrenia (e.g., IL3, IL4, IL9, NEUROG1).
In addition, it is striking that many of the remaining genes are
reported to be associated with immune diseases, including asthma,
Crohn’s disease and type-I diabetes. The prevalence of asthma
[14] and diabetes has been reported to be increased in patients
with schizophrenia. The association with diabetes is not merely
due to disease-related factors as the prevalence of diabetes is also
increased in the relatives of schizophrenia patients and familial
(e.g., genetic) factors may play a role [15]. Furthermore, there is
increasing evidence of immune involvement in schizophrenia [16].
Therefore, the finding of many immune-related genes in the 5q
region seems to further substantiate the segment-wise approach.
Regarding previous work, we note that the method used in the
current study may complement previous GWA studies. A large
number of weakly associated SNPs could result in a highly
significant segment-wise association while each individual SNP
would fail to survive multiple testing correction. Conversely, a
single highly significant SNP, with a sufficiently low p-value to
survive Bonferroni correction, would be insufficient to highlight
the whole segment containing it.
Recently, the findings of three multicenter studies were reported
[1,17,18]. In the study of Stefansson and colleagues, a variant
upstream of neurogranin (NRGN; p=2.461029) reached genome-
wide significance. A meta-analysis of the three GWA studies (8,008
cases and 19,077 controls) identified a cluster of genome-wide
significant SNPs in substantial LD in the MHC region on
chromosome 6p22.1 [1,17,18]; this region was not consistently
replicated in our segment-wise analyses. Although no segment
reached our cut-off for statistical significance, when we specifically
tested this region (chromosome 6: 26–28 Mb), we did find an
increased number of nominally significant SNPs in each sample
(p = 0.049 for Utrecht, p = 0.03 for GAIN, p= 0.009 for German;
Fisher’s combined probability test p = 0.001). Beyond the meth-
odological points mentioned above, the lack of statistical
significance may be explained by the fact that, although the
MHC region is quite large, spanning almost 5 Mb, the five
genome-wide significant markers cover ,2 cM [18]. It is possible
that correction for linkage disequilibrium with permutation-based
significance testing reduced the power to detect such relationships.
In conclusion, we found an association between schizophrenia
and a large (8 Mbp) chromosomal region, spanning multiple
genes. The segment-wise method proposed here complements a
single SNP analysis as it increases the chance of detecting
association which is clustered in a region but does not detect
association if it is actually limited to one or few single SNPs.
Further studies (e.g., based on the analysis of patterns of gene
expression) are needed to gain more knowledge on the mecha-
nisms which explain the clustering of genetic information in large
segments of the genome.
Materials and Methods
Study Samples
All three schizophrenia GWA data sets have been described
before. Briefly, the first set consists of 728 schizophrenia patients
and 653 healthy controls from The Netherlands genotyped with
the Illumina HumanHap550 BeadArrays [18]. The second
sample includes 1,172 patients diagnosed with schizophrenia
Table 3. Results of the sensitivity analyses: a comparison of different nominal p-values.
Nominal p-value p (Netherlands) p (GAIN) p (Germany)
Fisher’s combined
probability test
.05 0.001 0.023 0.001 3.98 E-6
0.01 0.002 0.04 0.06 4.2 E-4
0.1 0.001 0.001 0.003 6.4 E-7
EIGENSTRAT 0.004 0.001 0.04 2.23 E-5
Note. Results for variations of the method for the 32 Mbp width region on chromosome 5, 128–160 bp. Nom 0.01: the analysis was performed using p= 0.01 as the
cutoff for nominal SNP-wise significance. Nom 0.11: the analysis was performed using p= 0.1 as the cutoff for nominal SNP-wise significance. EIGENSTRAT: the analysis
was performed on data corrected for population stratification using the EIGENSTRAT procedure.
doi:10.1371/journal.pone.0038828.t003
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and 1,378 healthy controls of European descent from Molecular
Genetics of Schizophrenia (MGS) dataset phase I for which
genotypes were provided by the Genetic Association Information
Network (GAIN) from the Affymetrix 6.0 array [17]. The third
sample comprised 485 schizophrenia patients (described in
Stefansson et al. [18]) and 1,363 population-based controls
(described in Treutlein et al. [19]) from Germany genotyped with
Illumina HumanHap550 BeadArrays.
Ethics Statement
The studies were approved by the standing ethics committee,
and all subjects gave written informed consent in accordance with
the committee’s guidelines.
Statistical Analysis
All chromosomes from one to 22 were divided into segments of
varying width (see below), overlapping by 50%. For each SNP in
the segment an adjusted Armitage trend test was performed (i.e., a
test of the correlation of the number of rare alleles in the genotype
and the phenotype). For each segment, it was tested whether the
number of nominally (p,.05) significant SNPs in the segment was
higher than expected by chance. Linkage disequilibrium was
accounted for by using permutation testing, in which case-control
status was randomized using 1000 permutations. In this way, each
segment was associated with a p-value for the number of nominally
significant associated SNPs it contained: this p-value was termed
the metasignificance. The method was explored using a range of
segment widths: 2, 4, 8, 16, and 32 Mbp. The significance level
was corrected for the number of tests in the worst-case scenario,
i.e., the number of tests when using segments of 2 Mbp width.
Thus the probability of a false positive was at least Bonferroni-
controlled at 0.05 for each segment width, and analyses involving
different segments widths (and hence a different number of
metasignificance tests) did not differ in terms of statistical
threshold. The worst-case number of tests was 2729 which
required a Bonferroni corrected p-value of 1.8 E-5. A segment was
considered significant if the p-value was below the nominal
criterion of p=0.0264 in all three samples, so that the chance of a
false positive occurring in all three independent samples was the
required 0.0264L3= 1.8 E-5. Note that tests were one-sided: only
an increased number of SNPs in a segment would be considered a
significant result for a sample, regardless of the p-value. This allows
the probability of a compound event of a segment being significant
at 0.0264 in all three independent samples to be calculated as the
0.0264L3= 1.8 E-5. Analyses were performed using custom
software in Matlab (The MathWorks, Inc, 1984).
We acknowledge that statistical power using this approach will
depend on a number of factors, including the power of the
individual SNP tests, the number of participants, the number of
SNPs measured in each segment, and the correction for multiple
testing. In the current study, the choice was made to be reasonably
strict in terms of correction; in future work, the statistical power
could be increased by considering only broader segments which
would decrease the number of tests. Since we aimed to thoroughly
explore the sensitivity of our method to the specific segments sizes
used, we used a strict correction for the total number of tests at
segment size 2 Mbp. We did not correct for the total number of
segment sizes tested since the overlap between segment sizes would
be considered to be problematic and the tests of different segment
sizes in the same region can be expected to be highly correlated.
Correction for the total number of segment sizes would therefore
result in tests which are overly conservative.
Further, the permutation procedure introduces noise in the
results, which could present a problem for results that are close to
the threshold for sample-wise significance. To address this, we also
calculated Fisher’s combined probability test for the combination
of p-values over the sample. This method is less sensitive to
thresholding and may be more robust, but tests a somewhat
different null hypothesis than the compound-significance test of
replicability. We note that when testing all segments using Fisher’s
combined probability test, highly similar results to the compound-
significance test were found. No additional regions were found that
could have been undetected due to power problems with the
compound event approach. Furthermore, for the 16 and 32 Mbp
segment widths, p-values were lower such that the tests survived
Bonferroni correction for all tested segments summed over all
segment widths.
In follow-up analyses focussed on the 32 Mbp segment,
potential artefacts due to population stratification were accounted
for by adjusting case/control status for the first 10 EIGENSTRAT
components [10]. Logistic regression was used with the binary
variable encoding case– control status as a dependent variable and
the EIGENSTRAT components as independent variables. The
residual scores were used in subsequent statistical analyses.
Further, the analyses were repeated for different nominal
significance cut-offs per SNP, in order to determine the robustness
of the method to this parameter.
The UCSC Genome Bioinformatics site (http://genome.ucsc.
edu/) was used to find genes previously found to be associated with
disease in the region. The March 2006 (NCBI36/hg18) was used
to identify Phenotype and Disease Associations using the GAD
view. Furthermore, we have used the Schizophrenia Research
Forum (www.schizophreniaresearchforum.org) [20] to obtain
information on genes that have previously reported to be
associated with schizophrenia. Searches were performed at
October 6, 2011.
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